News & Updates

Show Multimedia Only
Immune-related adverse events portend better prognosis in ICI-treated hepatocellular carcinoma

Immune-related adverse events portend better prognosis in ICI-treated hepatocellular carcinoma

08 Mar 2022 byJairia Dela Cruz

Among advanced hepatocellular carcinoma patients being treated with immune checkpoint inhibitors (ICIs), the occurrence of multisystem and more severe immune-related adverse events is a favourable signal, being associated with survival advantage, according to a Singapore study.

Immune-related adverse events portend better prognosis in ICI-treated hepatocellular carcinoma

08 Mar 2022
AChEI use ups lung cancer risk in older, comorbid patients

AChEI use ups lung cancer risk in older, comorbid patients

07 Mar 2022
T2D risk elevated in thyroid cancer patients after thyroidectomy

T2D risk elevated in thyroid cancer patients after thyroidectomy

05 Mar 2022

Development of type 2 diabetes (T2D) is more likely to occur among patients with thyroid cancer who underwent thyroidectomy than matched controls, a Korea study has shown. In addition, a U-shaped dose-dependent relationship exists between the levothyroxine dosage and T2D risk.

T2D risk elevated in thyroid cancer patients after thyroidectomy

05 Mar 2022